Etrasimod
- Generic Name
- Etrasimod
- Brand Names
- Velsipity
- Drug Type
- Small Molecule
- Chemical Formula
- C26H26F3NO3
- CAS Number
- 1206123-37-6
- Unique Ingredient Identifier
- 6WH8495MMH
- Background
Etrasimod is a synthetic next-generation selective Sphingosine 1-phosphate (S1P) receptor modulator that targets the S1P with no detectable activity on S1P and S1P receptors. S1P receptors are membrane-derived lysophospholipid signaling molecules that are involved in the sequestration of circulating peripheral lymphocytes in lymph nodes. Therefore, S1P recep...
- Indication
Etrasimod is indicated for the treatment of moderately to severely active ulcerative colitis (UC) in adults.
- Associated Conditions
- Moderately to Severely Active Ulcerative Colitis
- Associated Therapies
- -
Safety and Efficacy of Oral Etrasimod in Adult Participants With Moderate-to-Severe Alopecia Areata
- First Posted Date
- 2020-09-21
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 80
- Registration Number
- NCT04556734
- Locations
- 🇺🇸
UPMC Department of Dermatology, Pittsburgh, Pennsylvania, United States
🇺🇸UPMC Eye Center, Pittsburgh, Pennsylvania, United States
🇺🇸Investigate MD, Scottsdale, Arizona, United States
A Phase 3 Study of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis
- Conditions
- Interventions
- First Posted Date
- 2019-11-25
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- Everstar Therapeutics Limited
- Target Recruit Count
- 341
- Registration Number
- NCT04176588
- Locations
- 🇨🇳
The First Affiliated Hospital of Fourth Military Medical University, PLA, Xi'an, Shanxi, China
A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease
- First Posted Date
- 2019-11-21
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1175
- Registration Number
- NCT04173273
- Locations
- 🇺🇸
Norman Endoscopy Center, Norman, Oklahoma, United States
🇵🇱Centralny Szpital Kliniczny MSWiA w Warszawie, Warszawa, Poland
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis
- First Posted Date
- 2019-06-24
- Last Posted Date
- 2022-12-21
- Lead Sponsor
- Arena Pharmaceuticals
- Target Recruit Count
- 354
- Registration Number
- NCT03996369
- Locations
- 🇨🇱
Hospital Sotero del Rio, Santiago, Chile
🇮🇳Midas Multispeciality Hospital Pvt.Ltd., Nagpur, Maharashtra, India
🇯🇵Nara Medical University Hospital, Kashihara-city, Nara, Japan
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
- First Posted Date
- 2019-05-15
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 778
- Registration Number
- NCT03950232
- Locations
- 🇧🇪
AZ Delta Roeselare VZW Campus, Roeselare, Belgium
🇫🇷CHU Nantes - Hôtel Dieu, Nantes, France
🇩🇪Krankenhaus Waldfriede e.V.,, Berlin, Germany
Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis
- First Posted Date
- 2019-05-10
- Last Posted Date
- 2022-12-20
- Lead Sponsor
- Arena Pharmaceuticals
- Target Recruit Count
- 433
- Registration Number
- NCT03945188
- Locations
- 🇺🇸
Digestive Health Specialists of the Southeast, Dothan, Alabama, United States
🇺🇸Om Research, LLC, Lancaster, California, United States
🇲🇽InspirePharma S. de R. L. de C.V., Monterrey, Nuevo León, Mexico
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
- First Posted Date
- 2015-08-31
- Last Posted Date
- 2021-11-26
- Lead Sponsor
- Arena Pharmaceuticals
- Target Recruit Count
- 118
- Registration Number
- NCT02536404
- Locations
- 🇺🇸
Arena 1142, Traverse City, Michigan, United States
🇺🇦Arena 1433, Uzhgorod, Ukraine
🇺🇸Arena 1115, Seattle, Washington, United States
Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis
- First Posted Date
- 2015-05-18
- Last Posted Date
- 2021-04-05
- Lead Sponsor
- Arena Pharmaceuticals
- Target Recruit Count
- 156
- Registration Number
- NCT02447302
- Locations
- 🇺🇸
Arena 1103, Ogden, Utah, United States
🇧🇬Arena 1409, Sofia, Bulgaria
🇺🇸Arena 1102, Hermitage, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.